Fig. 2From: Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatmentOlaparib + durvalumab + tremelimumab combination therapy dosing scheduleBack to article page